Citeline Podcasts

Since becoming a standalone consumer health company, Haleon has been driving awareness of public health issues such as chronic pain and children’s oral health. In this episode of Over the Counter, HBW Insight catches up with Haleon vice president and general manager Great Britain and Ireland Bas Vorsteveld, to find out more about why having a purpose is so important to establishing and growing a consumer health brand, looking in particular at the firm’s recent Aquafresh campaign, which saw it team up with British photographer, Rankin, to capture powerful portraits of children’s growing teeth to encourage them to be more confident. We also talk about Haleon’s ambitious climate commitments, and why ambition is important, alongside transparency about the challenges that such ambition brings.

2:00 – Introductions

2:50 – Aquafresh x Rankin

8:00 – The Importance of Having a Purpose

12:15 – Advantages of Being a Standalone

15:30 – Sustainability as Purpose

19:20 – Leading by Example

23:20 – Aiming High

25:20 – Being Transparent’

26:50 – Haleon’s Two-Year Anniversary

30:00 – VMS Growth and Preventative Health

32:20 – Pain Against the Grain

37:00 – The Year Ahead

Pink Sheet reporter and editors discuss former Surgeon General Jerome Adams’ views on how the FDA can better ensure clinical trial diversity (:27), questions about approving a new drug that would be used with a standard of care regimen that is off-label (15:00), and the agency beginning to schedule fully in-person advisory committee meetings (24:03).

More On These Topics From The Pink Sheet

‘You Shall Not Pass:' Former Surgeon General On Why US Government Should Push Trial Diversity: https://pink.citeline.com/PS155063/You-Shall-Not-Pass-Former-Surgeon-General-On-Why-US-Government-Should-Push-Trial-Diversity

Gaps Found In Most Pharma Trial Diversity Policies: https://pink.citeline.com/PS155086/Gaps-Found-In-Most-Pharma-Trial-Diversity-Policies

Zevra’s Arimoclomol Use With Standard Of Care Complicates US FDA Adcomm Efficacy Assessment: https://pink.citeline.com/PS155091/Zevras-Arimoclomol-Use-With-Standard-Of-Care-Complicates-US-FDA-Adcomm-Efficacy-Assessment

Back To White Oak: US FDA Adcomms Go Fully In-Person, Starting With Antimicrobials Panel: https://pink.citeline.com/PS155100/Back-To-White-Oak-US-FDA-Adcomms-Go-Fully-InPerson-Starting-With-Antimicrobials-Panel

In this audio, Dr. Anthony Fritz discusses Type 2 diabetes and the benefits of SGLT2 inhibitors. Learn how this treatment option can improve diabetes care.

올해 상반기 일라이 릴리와 노보 노디스크의 주가가 가장 높은 상승세를 보인 반면, BMS와 길리어드의 주가는 가장 큰 폭으로 하락했습니다.  Scrip의 글로벌 제약주 동향 기사를 요약한 내용입니다.

https://scrip.citeline.com/SC150593/Obesity-Rules-Large-Cap-Stocks-In-First-Half-Of-2024

Audio roundup of selected biopharma industry content from Scrip over the business week ended 2 August 2024. In this episode: Pfizer bullish on its oral GLP-1; BMS’s rising confidence about Medicare pricing of Eliquis; more long term data for Leqembi; NewAmsterdam’s CETP inhibitor shows promise; and a look at Mankind’s Bharat Serums buy.

https://scrip.citeline.com/SC150698/Quick-Listen-Scrips-Five-MustKnow-Things

Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Pink Sheet reporter and editors discuss the US FDA drug approval decisions that could arrive in August (:34), a trial design issue that could ensnare BMS’ Opdivo along with AstraZeneca’s Imfinzi (10:11), and the EMA potentially asking all sponsors to provide raw clinical data as part of application reviews (33:14).

More On These Topics From The Pink Sheet

Dozen Novel Agents Dream Of August US FDA Approval: https://pink.citeline.com/PS155070/Dozen-Novel-Agents-Dream-Of-August-US-FDA-Approval

BMS’s Opdivo May Be Next Casualty Of US FDA’s Perioperative Trial Redesign Push: https://pink.citeline.com/PS155056/BMSs-Opdivo-May-Be-Next-Casualty-Of-US-FDAs-Perioperative-Trial-Redesign-Push

EU Pilot On Raw Data Analysis Shows Benefits For Streamlining Medicines Evaluation: https://pink.citeline.com/PS155059/EU-Pilot-On-Raw-Data-Analysis-Shows-Benefits-For-Streamlining-Medicines-Evaluation

RNK Pharma founder and CEO Yaning Wang joins Brian Yang to discuss Shanghai's latest biopharma stimulus policies and the globalization of China biotech. Dexter Yan also discusses China biotech initial public offerings in the first half of this year.

COPD expert Wen-Yu discusses what the entrance of biologics might mean for the COPD treatment landscape and shares a sneak peek from her upcoming patient-based forecast.

Other platforms (in addition to SoundCloud):​

Apple Podcasts -   https://podcasts.apple.com/us/podcast/pharma-intelligence-podcasts/id923189836​

Google Podcasts - https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5zb3VuZGNsb3VkLmNvbS91c2Vycy9zb3VuZGNsb3VkOnVzZXJzOjEwNjU1NDkyOC9zb3VuZHMucnNz​

TuneIn - https://tunein.com/podcasts/Business--Economics-Podcasts/Pharma-Intelligence-Podcasts-p1140128/​

Spotify Podcasts - https://open.spotify.com/show/3DTc3eIh4xI6pVOd6DdO67

Join us for an insightful Q&A session on the treatment of multiple myeloma with Oncologist Dr. Joshua Richter. In this video, Dr. Richter shares his expert knowledge on the latest advancements, treatment options, and patient care strategies for multiple myeloma.

Consumers are expecting more and more from health and wellness brands, PA Consulting’s latest Brand Impact Index shows. Consumer health brands that link wellness to the sanctuary of the home do particularly well, explains PA consumer product expert Rhea Patten, on the latest episode of HBW Insight’s Over the Counter podcast. But do consumers expect too much? Do consumer heath companies really have a responsibility to help save the world? Patten says yes, and stresses that doing so will ultimately provide greater opportunities for brand impact and ultimately business growth.